ContraveExtended-Release (PD-Rx Pharmaceuticals, Inc.)
Welcome to the PulseAid listing for the Contrave drug offered from PD-Rx Pharmaceuticals, Inc.. This Opioid Antagonist [EPC],Opioid Antagonists [MoA],Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | PD-Rx Pharmaceuticals, Inc. |
NON-PROPRIETARY NAME: | naltrexone hydrochloride and bupropion hydrochloride |
SUBSTANCE NAME: | NALTREXONE HYDROCHLORIDE; BUPROPION HYDROCHLORIDE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Opioid Antagonist [EPC],Opioid Antagonists [MoA],Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET, EXTENDED RELEASE |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2014-10-22 |
END MARKETING DATE: | 0000-00-00 |
Contrave Extended-Release HUMAN PRESCRIPTION DRUG Details:
Item Description | Contrave Extended-Release from PD-Rx Pharmaceuticals, Inc. |
LABELER NAME: | PD-Rx Pharmaceuticals, Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 8; 90(mg/1; mg/1) |
START MARKETING DATE: | 2014-10-22 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 43063-772_52159413-ff52-13a3-e054-00144ff8d46c |
PRODUCT NDC: | 43063-772 |
APPLICATION NUMBER: | NDA200063 |
Other NALTREXONE HYDROCHLORIDE; BUPROPION HYDROCHLORIDE Pharmaceutical Manufacturers / Labelers: